Related Experiment Video
Updated: Jul 4, 2026

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Exploring the efficacy and safety of perampanel in epilepsia partialis continua: A case series
Setareh Lahsaee1, Kristin M Ikeda1, Stephanie Woodroffe1
1Department of Medicine (Neurology), Dalhousie University, Halifax, Nova Scotia, Canada.
Background:
Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus (SE), which is commonly drug-resistant requiring treatment with multiple antiseizure medications (ASM). There are no established guidelines for pharmacological management. Perampanel (PER), an AMPA receptor antagonist, has gained attention in treating SE based on limited case reports. This study evaluates the efficacy of PER in treating EPC.
Methods:
We retrospectively analyzed the treatment response and adverse effects of PER in patients with EPC at our local centre between January 2024 and March 2025. Eight patients with EPC were included. The loading dose of PER ranged from 6 mg to 20 mg. A clinical response was defined as seizure freedom within 72 h of initiating PER, with PER being the last ASM added.
Results:
PER resulted in seizure termination in eight out of eight patients. Time to response ranged from less than 24 h to 72 h. Oral PER, up to a dose of 16 mg, was well-tolerated in conscious patients. Common side effects included sedation, delirium, agitation, and nausea.
Conclusions:
Our real-world data suggest that PER is an effective and well-tolerated early adjunct therapy in EPC, particularly at higher oral loading doses in conscious patients.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Epilepsy ll: Types
Electroconvulsive Therapy
Antiepileptic Drugs: Glutamate Antagonists
Seizures l: Introduction
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

